

A Case Report

A Case of Alport Syndrome in an 18-Year-Old Male: Clinical Presentation, Diagnosis, and Multidisciplinary Management

Ahmad Zeb¹. Sayyeda Aisha Bahar²

^{1,2}Department of internal Medicine Ayub Teaching Hospital Abbottabad, Kpk Pakistan.

ABSTRACT

Alport syndrome is a rare genetic disorder characterized by progressive kidney failure, sensorineural hearing loss, and eye abnormalities. We present the case of an 18-year-old male with shortness of breath and cough with sputum, who was found to have a family history of kidney disease and suffered progressive vision and hearing loss since the age of 10. The patient was diagnosed with Alport syndrome based on clinical criteria. He underwent dialysis and was referred to specialists for management of his vision and hearing loss. The diagnosis and management of Alport syndrome are discussed, highlighting the importance of early diagnosis and timely intervention.

Keywords: *Alport syndrome, Genetic disorder, Kidney failure, Hearing loss, Eye abnormalities*

How to Cite this Article : Zeb A, Bahar SA. A case of Alport syndrome in an 18-year-old male: clinical presentation, diagnosis, and multidisciplinary management. *J Bacha Khan Med Coll.* 2023;4(1):45–47. [doi:10.69830/jbkmc.v4i01.85](https://doi.org/10.69830/jbkmc.v4i01.85)

Correspondence: Sayyeda Aisha Bahar²
Department of internal Medicine Ayub Teaching Hospital Abbottabad
Email: ayeshagul794@gmail.com

Article Tracking
Received: 21-01-2023
Revision: 12-02-2023
Accepted: 20-04-2023
Published: 05-07-2023

INTRODUCTION

Alport syndrome is a hereditary nephropathy. It is caused by mutations in type IV collagen genes COL4A3, COL4A4, and COL4A5 that lead to defective basement membranes in kidneys, ears and eyes(1). It is most commonly inherited as an X-linked disorder. The disease exhibits significant phenotypic variability depending on the pattern of inheritance and type of mutation(2). Here, we present a case of patient with Alport syndrome.

CASE REPORT

An 18-year-old male presented to emergency department with shortness of breath and cough with sputum. His father gave a history of abdominal discomfort, decreased oral intake and vomiting for past few months. Upon evaluation he had bibasilar lung crackles and peripheral edema. Labs showed decreased hemoglobin(7g/dl), creatinine of 10.8mg/dl and blood urea of 208mg/dl. His arterial blood gases revealed pH 7.35, HCO₃ 12.9 mmol/L and pCO₂ 23 mmHg. After initial stabilization, patient was admitted in our medical ward. On systemic review, it was found that patient has progressively decreased vision as well as decreased hearing since the age of 10 years. He also had family history of death in maternal uncle at a young age of 25 years due to complications of CKD.




Figure 1. Pedigree chart showing x-linked pattern of inheritance. Arrow=patient On examination, patient had sallow complexion, poor physical growth with thin extremities, protruding ears and half and half nails. Eye examination was remarkable for anterior lenticonus and audiogram showed bilateral sensorineural hearing loss.





Figure 2a. Anterior lenticonus. 2b. Audiogram showing sensorineural hearing loss

Further labs revealed RBCs in urine (10-20/HPF) and proteinuria +++. Ultrasound showed normal sized kidneys with grade III echogenicity. This patient met the clinical criteria for Alport syndrome(3).

MANAGEMENT

Patient was diagnosed with CKD and had few sessions of dialysis that led to significant improvement of his symptoms. Patient was referred to an ophthalmologist and ENT specialist for management of respective problems. A follow-up appointment was arranged with a nephrologist to decide on starting angiotensin converting enzyme inhibitor. Parents were counselled regarding the disease, genetic testing and treatment options as well as about evaluation of mother and siblings and that how early diagnosis and treatment can be beneficial.

DISCUSSION

Alport syndrome is a hereditary nephropathy diagnosed by combination of clinical features, family history and genetic testing. Early diagnosis is crucial because timely intervention can greatly benefit the patients. There is evidence showing the effectiveness of using angiotensin converting enzyme(ACE)

inhibitors to slow down the progression of renal disease and thus delaying the need for replacement therapy and transplant(1,2). The diagnosis should be considered in patients with hematuria detected on urinalysis and family history of kidney disease(3). Treatment at this point is only aimed to slow progression of renal disease. Hearing aids can help with the sensorineural deafness. Emerging therapies for Alport syndrome, such as antisense oligonucleotide(ASO) and others are being investigated and may provide disease-modifying treatment in the future(4).

Disclaimer: Nil

Conflict of Interest: Nil

Funding Disclosure: Nil

Authors Contribution

Concept & Design of Study Ahmad Zeb1

Drafting: Sayyeda Aisha

Bahar2 **Data Analysis:**

Sayyeda Aisha Bahar2

Critical Review: Ahmad Zeb1

Approval of version: All Mention Authors

Approved the Final version .

REFERENCES

1. Kashtan CE. Alport Syndrome: Achieving Early Diagnosis and Treatment. *Am J Kidney Dis.* 2021;77(2):272–9. doi.org/10.1053/j.ajkd.2020.09.015
2. Nozu K, Nakanishi K, Abe Y, Udagawa T, Okada S, Okamoto T, et al. A review of clinical characteristics and genetic backgrounds in Alport syndrome. *Clin Exp Nephrol.* 2019;23(2):158–68. <https://doi.org/10.1007/s10157-018-1633-3>
3. Flinter F. Alport's syndrome. *J Med Genet.* 2020;34(4):326–30. <https://doi.org/10.1136/jmg.34.4.326>
4. Gross O, Licht C, Anders HJ, Hoppe B, Beck B, Tönshoff B, et al. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. *Kidney Int.* 2019;81(5):494–501. <https://doi.org/10.1038/ki.2011.345>



Open Access Statement

This article is published in the *Journal of Bacha Khan Medical College* and is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). This license permits unrestricted use, distribution, adaptation, and reproduction in any medium or format, provided that appropriate credit is given to the original author(s) and the source, a link to the license is provided, and any changes made are clearly indicated. Images or other third-party materials in this article are included in the article's Creative Commons license unless stated otherwise in a credit line. If any material is not included under the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you must obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023. Published by Journal of Bacha Khan Medical College, Mardan, Pakistan